Background-Fetal long QT syndrome (LQTS) is associated with complex arrhythmias including torsades de pointes and 2°atrioventricular block. Sinus bradycardia has also been associated with fetal LQTS, but little is known of this rhythm manifestation. Our purpose was to characterize the fetal heart rate (FHR)/gestational age (GA) profile of fetal LQTS. Methods and Results-We ascertained fetal LQTS subjects by family history (Group 1) or fetal arrhythmia referral (Group 2). We compared FHR in LQTS subjects versus normal fetuses. To identify FHR predictors of LQTS, we calculated a bradycardia index as % of LQTS FHR recordings either Յ110 beats per minute (obstetric standard) or Յ3 rd percentile for GA. Among 42 LQTS subjects, 26 were in Group 1 and 16 in Group 2. There were 536 normal fetuses. The bradycardia index was only 15% for FHR Յ110 beats per minute, but 66% for FHR Յ3rd percentile for GA. Ten fetuses with complex arrhythmias also had severe and sustained sinus bradycardia throughout gestation. Identifying a fetal proband in Group 2 resulted in LQTS diagnosis in 9 unsuspected members of 6 families.
L ong QT syndrome (LQTS) is reported to have an incidence of 1 in 2500 individuals. Although QT interval prolongation may be an incidental finding, LQTS typically presents in adolescence or young adult life with syncope, sudden death, or cardiac arrest. 1, 2 Less frequently, LQTS presents in the perinatal (fetal/neonatal) period; in this setting morbidity and mortality are high, and torsades de pointes (TdP) and 2°atrioventricular (AV) block are signature rhythms. [3] [4] [5] [6] Sinus bradycardia is also a manifestation of fetal LQTS and is reported to be more common than TdP and 2°AV block. For example, as many as 44% to 66% of fetuses diagnosed with LQTS presented with sinus bradycardia at 26 to 40 weeks of gestation. 3,6 -8 In most reports, a fetal heart rate (FHR) Յ110 beats per minute (bpm) at any gestational age (GA) raised suspicion of LQTS. Indeed, FHR of Յ110 bpm at any GA is the obstetric definition of sinus bradycardia. 9 However, little is known of the sensitivity of this finding and how it relates to the subsequent diagnosis of LQTS.
Clinical Perspective on p 2695
It is well known that FHR in the normal fetus decreases during gestation from about 175 bpm at 10 weeks to 138 bpm at 40 weeks. This phenomenon is believed to be attributable to the increasing dominance of the parasympathetic nervous system on heart rate control as gestation progresses. 10, 11 Despite the association between fetal bradycardia and LQTS, the FHR/GA profile, or the range of FHRs of subjects with LQTS, has not been defined. We wondered whether there might be a pathological FHR in the setting of 1:1 AV conduction that was below normal for GA but Ͼ110 bpm that might be a sensitive marker for fetal LQTS. We hypothesized that the FHR/GA profile of LQTS individuals would be different than that of normal individuals and there might be GA-specific or genotypespecific FHR predictors of LQTS.
The purposes of this study were first to define the FHR/GA and rhythm profile of individuals with LQTS mutations and compare this profile with that of a normal control group. Second, we hoped to develop FHR criteria that would improve the recognition of LQTS in the perinatal period.
Methods
This was a study of fetal cardiac rhythm in pediatric subjects with a clinical and genetic diagnosis of LQTS. Participants were recruited at 3 medical centers (Advocate Hope and Lutheran General Children's Hospitals, Chicago IL; University of Tsukuba, Tsukuba, Ibaraki, Japan; and University of Utah and Primary Children's Medical Center, Salt Lake City, UT). Fetal heart rate in LQTS subjects across GA were compared with FHR from a normal control group across similar GA. Approval from the institutional review boards of each participating center was obtained.
Study Groups

Recruitment of LQTS Subjects
To avoid possible ascertainment bias, we divided LQTS subjects into 2 groups. Subjects in Group 1 had a family history of genetically confirmed LQTS and were under increased surveillance because of a risk of LQTS recurrence. Group 2 consisted of fetuses referred for evaluation of cardiac arrhythmia; in some cases Group 1 subjects were siblings of individuals in Group 2.
Recruitment of Normal Subjects
Normal subjects were recruited from Advocate Christ Medical Center and Hope Children's Hospital. Inclusion criteria were a normal obstetric ultrasound or a normal fetal echocardiogram. Indications for obstetric ultrasound of the normal subjects at 7 to 15 weeks were viability and nuchal translucency screening; indications for echocardiography of the normal subjects at 16 to 40 weeks were maternal diabetes mellitus, advanced maternal age, medication exposure or suspicion of fetal disease (eg, family history of a congenital heart defect). Exclusion criteria for normal subjects at 7 to 40 weeks GA included abnormal nuchal translucency measurement, fetal cardiac arrhythmia or history of arrhythmia, congenital heart defect, or clinically significant noncardiac malformation (eg, spina bifida), or known chromosome abnormality. The FHR of 12 infants evaluated for a maternal or paternal history of LQTS but with negative genetic testing were included in the normal subjects. No subject in the normal Group was related to any subject in LQTS Groups 1 or 2.
Fetal Heart Rate Measurements
LQTS Subjects
FHR of the LQTS subjects were obtained from obstetric records throughout the mother's pregnancy. They were derived from M-mode measurements of ventricular or atrial contractions from 5 consecutive cardiac cycles when the fetus was still, or by Doppler auscultation of the FHR routinely performed at monthly or twice monthly visits to the obstetric care provider. For fetuses with AV block, FHR was determined either during intermittent sinus rhythm or by measuring the atrial rate. Rhythms of LQTS subjects were classified as either sinus or complex, specifically TdP or 2°AV block.
Normal Subjects
Method for determination of FHR in normal fetuses was GAdependent. FHR at 7 to 15 weeks of gestation were measured from atrial or ventricular M-mode waveforms of 5 consecutive cardiac cycles obtained during routine obstetric ultrasounds. FHR at 16 to 40 weeks of gestation were measured from the aortic or pulmonary valve Doppler waveforms of 5 consecutive cardiac cycles obtained during fetal quiescence. Data were obtained from 10 fetuses for each week of gestation from 7 to 40 weeks.
LQTS Diagnosis
The diagnosis of LQTS was based on findings of a positive genetic test for LQTS. All genetic testing was performed in commercial genetic testing laboratories. Samples were tested for either 12 (GeneDx, Gaithersburg, MD) or 13 (Familion, Transgenomic Inc., New Haven, CT) LQTS gene subtypes. Only genetic variants reported to be deleterious were considered to be mutations; variants reported to be of uncertain significance were not considered pathological. Mutations were classified as LQTS gene type, compound (Ͼ1 deleterious mutation), uncharacterized (no mutation in a known LQT gene), or untested. The presence of a signature LQTS rhythm, TdP or 2°AV block, in the fetal or neonatal period was considered confirmatory of the LQTS diagnosis, even if genetic testing revealed no mutation in a known LQTS gene.
The QT interval on a postnatal 12 lead ECG was corrected (QTc) by both Bazett and Frederica formulas and reported for LQTS subjects. Subjects in Group 1 had an ECG at the time of their initial evaluation during infancy or childhood, whereas those in Group 2 had an ECG during the first 24 hours of life.
Fetal Heart Rate Analysis
We determined the 3rd, 50th, and 97th percentiles for FHR/GA of the normal subjects by logarithmic regression analysis. For the purposes of this study, we defined bradycardia in 2 different ways: either independent of GA (FHR Յ110 bpm, the obstetric definition of bradycardia) or dependent on GA (FHR Յ3 rd percentile for GA).
Statistical Analysis
The FHR (meanϮSE) was calculated for normal subjects and LQTS subjects. To maximize statistical power, we grouped the FHR data into 3 categorical GA groups, (1) Ͻ21 weeks, (2) 21 to 30 weeks, and (3) 31 to 40 weeks, and compared normal and LQTS FHR in the 3 GA groups. A mixed effect model was performed taking the dependency of patients within the same family into account. To eliminate maternal ␤-adrenergic blockade therapy as a confounding variable for observed FHR differences between normal and LQTS subjects, we compared FHR of treated and untreated mothers with LQTS by Mann-Whitney nonparametric testing. A 2-tailed P level of Ͻ0.05 was considered statistically significant. All analyses were done using SAS 9.2 (SAS Inc., Cary, NC).
Bradycardia Index of LQTS Subjects
Once we derived the 3rd, 50th, and 97th percentiles for the normal subjects at each GA, we calculated a bradycardia index for each LQTS fetus using both definitions of bradycardia. In other words, the bradycardia index was the ratio of FHR measures that were either Յ110 bpm or Յ3 rd percentile for GA compared with the total number of FHR measures for that fetus. Because the number of subjects in each genotype group was small, we did not seek to define a genotype-specific effect on FHR or bradycardia index within categorical age groups or between Groups 1 and 2.
Results
LQTS Subjects
The descriptions of the LQTS cohorts in Group 1 (referred with a family history of LQTS; nϭ26) and Group 2 (referred for arrhythmia evaluation; nϭ16) are summarized in Table 1 . Among the 42 subjects, a diagnosis of LQTS was made during fetal or neonatal life in 32 subjects; in 10 subjects in Group 1, the diagnosis was made later during infancy or childhood. The QTc intervals corrected by Bazett formula ranged from 450 to 700 (mean 582) ms and corrected by Frederica formula ranged from 394 to 660 (mean 471) ms. Bazett correction resulted in a prolonged QTc (Ն 450 ms) in 95% of genetically proven LQTS subjects, whereas use of Friderica correction identifies only 59% of genetically proven LQTS subjects as having a prolonged QTc. The corrected QT intervals by both formulae are shown in the Table I in the online-only Data Supplement. Several members of Group 1 were in previously reported families. [12] [13] [14] Siblings of 4 families were included in Group 1: subjects #10, #11, and #12; Numbers in parenthesis after subject number are references in which subject was previously described; numbers in parenthesis after mutations are references for first description of mutation. LQTS indicates long QT syndrome; No., number; GA, gestational age; FHR, fetal heart rate; wks, weeks; F/N, fetus/neonate; and IUFD, intrauterine fetal demise.
*Mother with LQTS was on beta blocker treatment during entire pregnancy. †Mother on ␤-blocker therapy only during 3rd trimester. ‡Novel mutation.
subjects #17 and #18, subjects #19 and #20, and subjects #21 and #22. Subjects #41 and #42 in Group 2 were twins. At the time of initial assessment, no Group 2 subject was known to have affected family members; however, subsequent diagnosis in the fetal proband led to a genetic diagnosis of LQTS in undiagnosed members of 6/16 (38%) families. These family members (subjects #5, #6, and #7) were included in Group 1 after diagnosis of LQTS in subjects #32, #33, and #37. The mean GA at delivery was slightly less for Group 2 (36.4Ϯ2.8 weeks) compared with Group 1 (38.0Ϯ2.7 weeks) subjects, but this difference was not significant (Pϭ0.08). The mean GA of referral for subjects in Group 2 was 27.6Ϯ4.5 weeks. Five subjects in Group 2 were delivered prematurely (Յ 35 weeks of gestation) because of uncontrolled arrhythmia or fetal distress; 1 fetus died in utero from uncontrolled arrhythmia and severe hydrops (Subject # 40).
Among mothers with LQTS, 13 were treated with ␤-adrenergic blocking agents during pregnancy: 11 throughout pregnancy and 2 during 3rd trimester only. The FHR was not different in fetuses whose mothers were treated (130.1Ϯ8.2 bpm) or untreated (127.5Ϯ13.6 bpm; Pϭ0.6).
LQTS Mutations in Group 1 Versus Group 2
Mutation in a known LQT gene was found in most subjects (92%) who underwent genetic testing (95%): 23 with LQT1, 4 with LQT2, 6 with LQT3, 2 with LQT5, and 1 with a compound mutation. Three subjects were not tested and 3 subjects had uncharacterized mutations. Among those who had genetic testing, there were differences in genetic results in Group 1 versus Group 2 subjects (Table  1) . For example, 83% of Group 1 subjects had a KCNQ1 or KCNE1 mutation, 4% had an SCN5A mutation, and no subject had an uncharacterized mutation. In contrast, 33% of Group 2 subjects had a KCNQ1 mutation, 33% had an SCN5A mutation, and nearly 20% had uncharacterized mutations (nϭ3).
Fetal Heart Rates
Normal FHR data from 7 to 40 weeks were obtained from 3264 FHR measurements in 547 normal subjects. The 3rd, 50th, and 97th percentiles for GA are shown in Figure 1 . We obtained 318 FHR measures from 42 LQTS fetuses; the mean of FHR measures was Ϸ8 per fetus and the range was 1 to 12 per fetus. The mean FHR at each of the 3 GA groups (Ͻ21 weeks, 21-30 weeks, and 31-40 weeks) was significantly different between normal and LQTS subjects (PϽ0.001; Table 2 ). The FHR at the 3rd percentile of normal from the 3 GA groups were all greater than the standard obstetric definition of fetal bradycardia (ie, FHR Յ110 bpm).
We evaluated the individual FHR measures across GA of fetuses based on indication for referral. Figure 2A shows the FHR/GA profile of subjects referred for a family history; Figure 2B shows the FHR/GA profile of subjects referred for evaluation of fetal rhythm. The FHR of the LQTS fetuses decreased with GA as seen in the normal 
The Bradycardia Index
Among LQTS subjects, only 15% of FHR readings were Յ110 bpm whereas 66% of the FHR readings were Յ3 rd percentile for GA. Thus, 85% of the total FHR readings were higher than the standard obstetric definition of bradycardia (FHR Յ110 bpm), and only 33% of the LQTS FHR readings were Ͼ3rd percentile for GA. Using FHR Յ3rd percentile for GA, 38% (16/42) of LQTS fetuses had a bradycardia index of 100% and 67% (28/42) had a bradycardia index between 75% to 100%. Table 3 shows there were significant differences between Groups 1 and 2 in the bradycardia indices for FHR Յ110 bpm and Յ3rd percentile for GA. Within Group 2, a bradycardia index of 100% was seen in 2/3 subjects with complex rhythms ( Table 4 ). The findings of more pronounced bradycardia in Group 2 subjects with complex rhythms may be another manifestation of a more severe phenotype in such fetal LQTS subjects.
Although the sample sizes of certain LQTS mutations were small, among genotypes, the bradycardia index for FHR Յ3rd percentile for GA was highest (100%) for uncharacterized mutations and lowest (0%) for LQT5 mutations. Overall, the severity of the bradycardia index was not predicted by the presence of mutations in known LQTS genes.
Fetal Heart Rhythms and FHR
In most of the 42 fetuses, sinus rhythm was observed throughout pregnancy, but in 10 fetuses, 8 of whom were in Group 2, complex arrhythmias characterized by 2°AV block or TdP were observed ( Table 4 ). The mean FHRs of these 10 subjects were lower across GA than those subjects who manifested only fetal bradycardia (120.74Ϯ3.56 versus 130.79Ϯ2.37; PϽ0.01), and the bradycardia indices for FHR Յ3rd percentile were higher (80% versus 60%).
Discussion
There are several novel and clinically relevant findings in this study of fetal LQTS. First, as in normal fetuses, the FHR of LQTS subjects trend downward but are generally lower than FHR of normal fetuses as gestation progresses. Second, there are GA-dependent FHR predictors of LQTS; for example, when compared with a GA independent FHR predictor (FHR Յ110 bpm), a FHR Յ3rd percentile for GA improves ascertainment of LQTS subjects from 15% to 85%. Third, there are shades of bradycardia within the LQTS population: compared with subjects who remained in sinus rhythm during pregnancy, subjects with the lowest FHRs were more likely to have had a complex arrhythmia including TdP or 2°AV block, and were more likely to have de novo or uncharacterized mutations. Together, findings from this study should improve ascertainment of fetal LQTS at all GA.
From the first ultrasound visualization of the fetal heart signifying a viable pregnancy to the reactive accelerations signifying fetal well-being during labor and delivery, FHR is the most frequently and thoroughly evaluated parameter from the beginning to the end of pregnancy. Yet, neither the range of normal nor the definitions of abnormal FHR are GA-specific, emphasizing the shortcomings of a single definition of fetal bradycardia (eg, FHR Յ110 bpm). Sinus bradycardia occurs in LQTS, but the molecular basis for this common occurrence is incompletely understood. Furthermore, the GA at which the sinus beat becomes bradycardic, and indeed the sensitivity and specificity of a GA-independent definition of bradycardia, are poorly understood.
Previous publications have described a range of sinus FHRs ranging from Ͻ100 to 130 bpm in LQTS fetuses. 7, 3, 4 As in our series, many of these LQTS fetuses with FHRs in the normal range (Ͼ 110 bpm) had a family history of LQTS. The higher FHR in those with a family history may be ascertainment bias as these subjects, screened preemptively, may be less severely affected. After birth, the majority of subjects, even those with FHR Յ110 bpm, had heart rates in the normal range. 7 Similarly, in a large study evaluating LQTS and SIDS, bradycardia in the neonate was not considered a risk factor for LQTS. 35 Thus, use of a stringent fetal bradycardia definition (ie, FHR Յ110 bpm) may result in failure to recognize fetal LQTS, and continuation of mild bradycardia (ie, heart rate Ͼ110 bpm) after birth may fail to raise the suspicion of LQTS in the neonate. This may explain why the older siblings of some fetal probands in this study with mild bradycardia were not suspected as fetuses or neonates to have LQTS.
In the absence of a known family history, the ascertainment of fetal LQTS is based on the correct and timely diagnosis of the signature LQTS rhythms. Although TdP and 2°AV block are usually easily recognized and have high specificity, they occur infrequently in the fetus with LQTS. For example, only 24% of our study cohort had these complex arrhythmias, and none of the 25 subjects in this report with LQT1 mutations had TdP or 2°AV block. Thus, it is important to identify other markers of LQTS; findings in our study suggest that FHR may be useful for this purpose. Our results show that a one size fits all FHR indicator of bradycardia will not be adequate. For example, the bradycardia index of LQT 1 subjects for FHR Յ110 bpm was only 2%, but definition of bradycardia as FHR Յ3 rd percentile yielded a bradycardia index of 68%. Using a GA-independent definition of bradycardia would not have led to suspicion of LQTS in many such subjects.
Although our study group is relatively small, we found associations between FHR, rhythm phenotype, and genotype, which could be helpful in the diagnosis of LQTS. For example, individuals with KCNQ1 mutations tended to have a mild phenotype in utero with sinus rhythm and mild bradycardia. On the other hand, genetically elusive subjects, with no known mutations and a negative family history of LQTS, had profound fetal bradycardia and complex rhythms.
Based on the results of this study, we believe that FHR Յ3rd percentile for GA is a superior definition of fetal bradycardia compared with the widely used obstetric definition. Our study suggests that the fetus with repeated FHR measurements Յ3rd percentile for GA without any other rhythm abnormality should be suspected of having LQTS. This suspicion should lead to detailed family history for LQTS. Regardless of family history, a postnatal 12-lead ECG should be examined for findings of LQTS. If the family history is positive, or the fetal proband manifests complex LQTS rhythms, ECG screening of firstdegree relatives is recommended. Even if family members are asymptomatic, ECG evidence of LQTS warrants genetic testing. Finally, if postnatal genetic testing of the fetus with suspected LQTS is positive, but clinical or genetic manifestations of LQTS are negative in firstdegree relatives, the possibility of parental mosaicism should be considered, especially if future pregnancies are contemplated. 36 
